BOSTON, Nov. 12, 2025 /PRNewswire/ -- Modulight Biotherapeutics, developer of novel optogenetic platform for the treatment of neurological disorders, announced today the closing of its Seed funding round raising $12.2 million. The Seed round was led by Jibe Ventures and LocalGlobe, with...
Hence then, the article about modulight biotherapeutics announces 12 million seed funding for novel optogenetic therapy to treat neurological disorders was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Modulight Biotherapeutics Announces $12 Million Seed Funding for Novel Optogenetic Therapy to Treat Neurological Disorders )
Also on site :
- Saratoga® Spring Water Steps Beyond the Bottle and onto the Runway with Public School New York Collaboration
- Superfood Gummies Are a ‘Game Changer’ for Picky Kids, and We Found Some Packed With Essential Nutrients
- Blue Bell Just Announced Its New Coffee-Inspired Ice Cream Flavor—And It’s Heading to Stores This Week